Visser Wieke C H, de Jong Hans, Melchers Willem J G, Mulders Peter F A, Schalken Jack A
Department of Product Development, MDxHealth BV, 6534 AT Nijmegen, The Netherlands.
Department of Medical Microbiology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Cancers (Basel). 2020 Dec 16;12(12):3790. doi: 10.3390/cancers12123790.
In the diagnosis and prognosis of prostate cancer (PCa), the serum prostate-specific antigen test is widely used but is associated with low specificity. Therefore, blood-, urinary- and tissue-based biomarker tests have been developed, intended to be used in the diagnostic and prognostic setting of PCa. This review provides an overview of commercially available biomarker tests developed to be used in several clinical stages of PCa management. In the diagnostic setting, the following tests can help selecting the right patients for initial and/or repeat biopsy: PHI, 4K, MiPS, SelectMDx, ExoDx, Proclarix, ConfirmMDx, PCA3 and PCMT. In the prognostic setting, the Prolaris, OncotypeDx and Decipher test can help in risk-stratification of patients regarding treatment decisions. Following, an overview is provided of the studies available comparing the performance of biomarker tests. However, only a small number of recently published head-to-head comparison studies are available. In contrast, recent research has focused on the use of biomarker tests in relation to the (complementary) use of multiparametric magnetic resonance imaging in PCa diagnosis.
在前列腺癌（PCa）的诊断和预后评估中，血清前列腺特异性抗原检测被广泛应用，但特异性较低。因此，已经开发了基于血液、尿液和组织的生物标志物检测，旨在用于PCa的诊断和预后评估。本综述概述了为用于PCa管理的几个临床阶段而开发的商用生物标志物检测。在诊断方面，以下检测有助于为初次和/或重复活检选择合适的患者：PHI、4K、MiPS、SelectMDx、ExoDx、Proclarix、ConfirmMDx、PCA3和PCMT。在预后评估方面，Prolaris、OncotypeDx和Decipher检测有助于对患者进行风险分层，以做出治疗决策。接下来，概述了比较生物标志物检测性能的现有研究。然而，仅有少数近期发表的直接比较研究。相比之下，近期研究集中在生物标志物检测与多参数磁共振成像在PCa诊断中的（互补）应用。
